The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives
Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence. The market for cancer testing are comprehensively covered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 5th. Edition. This report, authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:
Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up.
Kalorama Information reports are always based on primary research of the market with particular attention to important market trends that are more important to understand than today's numbers. Shara Rosen not only defines the marketplace and provides market numbers, but her report also examines trends that are driving cancer testing now and determining where it will go in the future. Some of the trends examined in this report include:
Personalized Cancer Testing and Advances In Precision
The phenomenon of test personalization comes under many guises – pharmacogenomic, pharmacogenetic, companion tests, and represents one of the fastest growing segments of the market for cancer tests. It has emerged fully from research into clinical practice. Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. Some personalized cancer tests are CE Marked and FDA-cleared and many more are in development. More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and are agreeing to pay for them.
This report covers those trends and has tables describing the following:
This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood - lymphomas, myelomas and leukemias - is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis. As such this report does not discuss area of hematological cancer diagnosis in great detail.
Market analysis in this report covers world markets for in vitro cancer diagnostics, however the reader will find a bias toward the developed areas of the globe -- N. America, Japan and Western Europe. However cancer is a growing global problem and where possible the report covers cancer testing in the more industrialized developing countries of Latin America and Asia Pacific.
The emphasis is on in vitro diagnostic tests, however a discussion of the role of diagnostics in cancer management, must include in vitro and in vivo tests. The two are inextricably linked. The same cell markers used in flow cytometry and antibodies used for immunoassays to detect elements of the immunity process are used as vectors for imaging agents to detect tumors and to monitor the extent of cancer metastasis.
In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles in several sections. Companies profiled include the following:
Beckman Coulter Inc./Danaher
Becton, Dickinson and Company
Bio-Rad Laboratories Inc.
IRIS International, Inc.
Ortho Clinical Diagnostics
Siemens Healthcare Diagnostics
Cynvenio Biosystems, Inc.
Epic Sciences Inc.
Fluxion Biosciences, Inc.
Sony DADC Biosciences
Advanced Cell Diagnostics
Amoy Diagnostics Co. Ltd.
Applied Spectral Imaging
Biocare Medical, LLC
CCC Diagnostics, Inc.
Caliper Life Sciences
Circadian Technologies Limited
Cymogen Dx, LLC
Diagnostic Biosystems (DBS)
DVS Sciences Inc.
DxTerity Diagnostics Inc.
Halo Healthcare Inc. (formerly NeoMatrix, LLC)
Horizon Discovery Ltd
Metamark Genetics, Inc.
Oxford Cancer Biomarkers
Philips Handheld Diagnostics
Theranostics Health Inc.
Ventana Medical Systems Inc.
Arbor Vita Corporation
Axela Biosensors, Inc.
Binding Site (The)
Fujirebio Diagnostics, Inc.
Gold Standard Diagnostics:
Nano Discovery Inc.
Oncimmune USA LLC
OPKO Health, Inc.
Polymedco Cancer Diagnostic Products, LLC
Radient Pharmaceuticals Corporation
Saladax Biomedical, Inc.
Adaptive Biotechnologies Corporation
Agilent Technologies Inc.
Arrayit Diagnostics Inc.
Enzo Biochem Inc.
Falcon Genomics, Inc.
GeneCentric Diagnostics, Inc.
Genetic Technologies Limited
Inform Genomics, Inc.
And Many More Companies..
Related Reports:Retail Clinics 2015: Growth of Stores, Consumer Opinion, Leading Competitors, Sales of Products to Clinics (Diagnostic Tests, Pharmaceuticals, Vaccines), Clinic Sales Forecasts and Trends
Mar 3, 2015 - KLI5479965 - $3,995.00
Implantable Infusion Pumps: World Market Analysis
Feb 26, 2015 - KLI5476346 - $1,500.00
Mergers and Acquisitions in the IVD Market
Feb 17, 2015 - KLI5470884 - $500.00
Global Orthopedic Device Market (Hip, Knee, Spine, Extremities and Trauma Devices)
Feb 10, 2015 - KLI5467092 - $3,500.00
The Market for In Vitro Diagnostic Tests in Latin America (Colombia, Brazil, Peru, Argentina, Chile, Venezuela, Ecuador and Other Nations)
Jan 31, 2015 - KLI5464816 - $4,995.00
Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)
Jan 23, 2015 - KLI5458715 - $4,200.00
Abbott Diagnostics: Company Profile
Jan 21, 2015 - KLI5442542 - $500.00
Roche Diagnostics: Company Profile
Jan 21, 2015 - KLI5442543 - $500.00
Siemens Healthcare: Company Profile
Jan 21, 2015 - KLI5442544 - $500.00
IVD Procedure Volumes and Pricing Analysis
Jan 14, 2015 - KLI5440452 - $3,995.00
Questions?Contact a research specialist >
Most Popular ResearchThe Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition The United States Market for In Vitro Diagnostic Tests The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives Retail Clinics Market Overview and 2014 Survey Results Bioinformatics in IVD Testing The Market and Potential for Molecular Point of Care Diagnostics